OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Washington - The humanized monoclonal antibody efalizumab, given once weekly subcutaneously, produces profound clinical improvement in moderate to severe plaque psoriasis, reported Craig Leonardi, M.D., at the American Academy of Dermatology's 59th annual meeting.